Czech University starts a clinical trial of early detection of Lung Cancer in high-risk asymptomatic individuals
Photo by Max Kleinen
Charles University (Czech Republic) is commencing recruitment for the clinical trial of the Early Detection of Lung Cancer in Czech High-risk Asymptomatic Individuals.
Outcomes of the study include:
- optimization of entry criteria, optimization of timing of a follow-up LDCT and management of the patients, proposal of quality assurance indicators;
- influence of screening on the stage of lung cancer at the time of the diagnosis and life-years lost;
- cost-effectiveness of the screening program;
- evaluation of the diagnostic yield for secondary findings (pulmonary fibrosis, cardiovascular risk).
The trial officially began on the August 1, 2020 and is planned to complete on December 31, 2023.
The population that can be enrolled into this study includes patients at the age 55-74 years who smoking (more than 30 pack-years, smoker or ex-smoker <15 years) with performance status (0-1) and can climb at least one floor without any difficulty or pause.
The number of cancers detected at stage I is primary outcome measure.
Charles University is the oldest and largest university in the Czech Republic. It is one of the oldest universities in Europe in continuous operation.
General University Hospital, Prague is the collaborator in this clinical trial.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04627350.
